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daily living (T-IADL) in carers of patients with Alzheimer’s disease (AD). Methods: 
GERAS is a prospective, non-interventional cohort study in AD patients and caregiv-
ers. The Zarit Burden Inventory (ZBI) and the EQ-5D were used to measure burden 
and HRQoL respectively. Spearman correlations were computed between EQ-5D, ZBI 
and T-IADL at baseline, 18-months and for change over 18-months. T-IADL and ZBI 
change scores were summarised by EQ-5D domain change category (better/stable/
worse). Results: 1495 caregivers were available at baseline [67 years (SD 12) and 
64% female]. According to baseline patient severity, caregivers’ EQ-5D health state 
values were 0.86, 0.85 and 0.82 and ZBI total scores were 25, 29 and 34 in mild, moder-
ate and moderately severe/severe AD respectively. T-IADL increased from a mean of 
79 hours (SD 89; median 60 hours) at baseline by a mean of 17 hours (SD 105; median 
10 hours) over 18-months, and showed a stronger correlation with ZBI than with 
EQ-5D, although correlations were low for both (e.g. change scores 0.118 ZBI; 0.020 
EQ-5D). Worsening within EQ-5D domains (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) was associated with the greatest increase in 
burden scores, although the majority of caregivers (68-90%) remained stable within 
each EQ-5D domain. Relative to these stable caregivers, larger increases in T-IADL 
over 18–months were associated with better ratings in mobility and usual activities 
but worsening in pain/discomfort. Larger increases in T-IADL were associated with 
both better and worse ratings in anxiety/depression [23.5 hours better (11%); 12.2 
hours stable (68%); 24.8 hours worse (16%)]. ConClusions: EQ-5D health state 
values had low sensitivity to changes in caregiver time over an 18-month period. 
ZBI may better reflect the impact of caring for AD patients.
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objeCtives: This systematic literature review (SLR) aimed to identify health state 
utility values among migraine patients. Methods: A SLR was conducted in bio-
medical databases and Health Technology Assessment (HTA) websites from 2000-
2014. Search terms included different combinations of migraine along with utility 
or quality-of-life measures. References of identified SLR/meta-analyses were inves-
tigated to identify additional studies. Each study was reviewed by two independent 
reviewers; disagreements were resolved by a third reviewer. Results: The search 
yielded 29 publications (including a submission to the National Institute for Health 
and Care Excellence) from which 23 studies were extracted. The studies were mainly 
conducted in US (n= 6), Canada (n= 5), or UK (n= 3). Sample sizes varied from 14 to 
> 8000. Age (mean: 21-47.5 years) was reported in 16 studies while disease duration 
(mean: 2.3-24 years) only in four. Proportion of females ranged between 70-80%. 
Pain and psychiatric disorders were the most common comorbidities. Migraine 
was primarily defined using the International Headache Society’s International 
Classification of Headache Disorders criteria (n= 10). Most studies used validated 
utility instruments: EQ-5D (n= 12), Health Utility Index-Mark 3 (n= 7) or SF-36 (n= 1) 
to assess utility values. Three studies used the Quality of Well Being scale, and two 
used custom questionnaires, using Time Trade Off or Standard Gamble techniques. 
Utilities values were reported using the following categories: by migraine pain sever-
ity (pain-free [0.87-0.96], mild [0.66-0.84], moderate [0.51-0.77] or severe [0.39-0.54]), 
by number of migraine days/month (or percentage reduction in migraine frequency: 
< 50% to ≥ 75% associated with a utility increase: 0.001 to 0.010), or by migraine type 
(chronic [0.43-0.89]/episodic [0.62-0.91]). ConClusions: This SLR confirmed that 
increased migraine frequency and pain severity were associated with lower utility 
values among migraineures. A wide range of utility values were reported; potential 
differences across reported estimates are likely due to different populations or dif-
ferent methodologies implemented to derive estimates.
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objeCtives: Treatment Satisfaction Questionnaire for Medication (TSQM) (score 
range 0-100) has been shown to be a reliable and valid instrument to measure 
patients’ satisfaction with their treatment for multiple sclerosis (MS). The 14-item 
TSQM Version1.4 provides scores across four domains: effectiveness, convenience, 
global satisfaction, and side effects. The abbreviated 9-item TQSM-9 excludes the 
side effects domain. Positive changes in score indicate improvement. We conducted 
a systematic review of clinical studies that reported MS patient satisfaction with 
their disease-modifying therapies (DMTs) using TSQM. Methods: We systemati-
cally searched EMBASE, MEDLINE, BIOSIS Previews and Medmeme with pre-specified 
search terms from 2004 onwards for manuscripts and conference proceedings of 
prospective MS studies. The outcomes of interest included study type, change from 
baseline (CFB) in TSQM scores by DMT group, and differences in CFB in TSQM across 
treatment groups. Results: Six studies met all study criteria (3 single-arm observa-
tional or surveillance studies and 3 randomized studies). The DMTs studied included 
interferon beta-1b, glatiramer acetate, fingolimod, teriflunomide, and natalizumab. 
Two studies used TSQM Version1.4, while four used TSQM-9. Study length ranged from 
12 weeks to 3 years. CFB at 6 months was the most commonly reported outcome. The 
CFB at 6 months on the effectiveness subscale ranged from 1.8 to 26.9, convenience 
subscale from 3.6 to 41.2, and global satisfaction subscale from 2.9 to 20.4. The CFB 
at 6 months was generally higher for natalizumab and fingolimod compared with 
injectable platform DMTs, although this finding may be confounded by the differ-
ences in study design and patient characteristics. ConClusions: Several MS studies 
have used the TSQM to measure patient satisfaction with DMTs. Comparisons across 
identified studies is challenging, as there is substantial heterogeneity with regards to 
version of TSQM used, study type and length, and type of analyses reported.
main contributor to societal costs. Although time on basic and instrumental ADLs 
differed across countries, some of this may be explained by use of community 
care services and institutionalization. Other resources had different patterns of 
use across countries, reflecting country-specific health and social care systems.
NeuroLogicaL DiSorDerS – Patient-reported outcomes & Patient Preference 
Studies
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objeCtives: To perform a systematic literature review of adherence to inhaled 
antibiotics for the treatment of chronic Pseudomonas Aeruginosa (PA) infection in 
patients with cystic fibrosis (CF). Methods: A systematic literature search of English-
language articles was conducted in April 2014 using Medline and Embase. No publica-
tion date limit was applied. The literature screening was conducted by 2 independent 
reviewers. All of the included studies were assessed for quality. Results: The search 
yielded 192 publications, of which 9 met the inclusion criteria and underwent data 
extraction. Six studies focused on inhaled tobramycin, 1 on inhaled colistimethate, 1 
on inhaled levofloxacin, and 1 on inhaled aztreonam lysine. Medication adherence to 
inhaled antibiotics was analyzed by pharmacy refill history, daily phone diary, parent 
and child self-reports, vials counting, or electronic monitoring. Proportion of adherent 
patients (≥ 75%/80% of required doses taken) in randomized clinical trials (n= 3) ranged 
from 86% to 97%; adherence rates in prospective cohort studies (n= 2) ranged between 
36% and 92%, and in retrospective studies (n= 4) ranged between 60% and 70%. The 
adherence to inhaled antibiotics in CF was found to be associated with the complex-
ity of treatment, time of drug administration, age of patients, treatment burden (i.e., 
adverse events, taste), and patient satisfaction. ConClusions: Adherence varied 
depending on the type of study, type of treatment, and method of measurement. In 
real-world trials, poor adherence to inhaled antibiotics was found in patients with CF. 
Regular routine adherence monitoring during CF care, discussion about sub-optimal 
adherence and treatment reinforcement on the basis of treatment burden, clinical 
status, and adverse events may help to better understand the predictors and the 
long-term consequences of non-adherence to inhaled antibiotics for the treatment 
of chronic PA infection in CF.
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objeCtives: Pharmacological management of relapsing-remitting multiple sclerosis 
(RRMS) includes the use of oral, injectable, or infusible Disease Modifying Therapies 
(DMTs). Achieving therapeutic goals in MS requires strict adherence to medication 
administration schedule. To assess compliance and discontinuation rates with DMTs 
in Canadian patients with RRMS. Methods: This non-interventional, retrospec-
tive analysis was based on private claims patient cohorts accessed through IMS Rx 
Dynamics®. Patients had at least one prescription filled for each DMT (oral: fingoli-
mod, dimethyl fumarate (DMF), teriflunomide; injectable (BRACE): interferon beta-1a, 
interferon beta-1b, glatiramer acetate; infusible: natalizumab). Patients were compli-
ant if the medication possession ratio (MPR) was ≥ 80%. Discontinuation rates were 
calculated based on patients who stopped therapy or who were switched to another 
DMT. Compliance and discontinuation rates were collected at 6-month intervals with 
compliance cohorts from August 2011 to December 2014 (rolling 36 months total) and 
discontinuation cohorts from September 2011 to January 2015. Results: Compliance 
data was collected for 10315 patients (fingolimod, n= 1524; DMF, n= 1828; terifluno-
mide, n= 456; natalizumab, n= 604; BRACE, n= 5903). Compliance rate across Canada 
was higher for fingolimod (78%) compared to other DMTs, including natalizumab 
(72%), DMF (70%), and BRACE (56%). In Quebec, fingolimod had a compliance rate of 
80%, higher than DMF (68%) and BRACE (65%). Patients on fingolimod had the low-
est discontinuation rate across Canada (22%), compared to natalizumab (30%) and 
BRACE (47%). In Quebec, DMF had a higher discontinuation rate (29%) than other orals 
(fingolimod, 20%; teriflunomide, 23%) and natalizumab (25%). ConClusions: In a 
Canadian real-world setting, the compliance rate with fingolimod was higher than 
for other DMTs while the discontinuation rate with fingolimod was lower compared 
to other DMTs. These findings may facilitate MS management strategies which may 
lead to improved clinical and economic outcomes. Findings based in part on data 
licensed from IMS Health Canada Inc. All Rights Reserved.
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objeCtives: To describe the relationship between caregiver health-related quality 
of life (HRQoL), caregiver burden and caregiver time for instrumental activities of 
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included in the top 10. Next, 185 patients evaluated the importance of 27 attributes 
in the BWS. Effect on disease progression was most important (RIS= 9.6), followed 
by quality of life (9.2), relapse rate (7.8), severity of side effects (7.6), relapse severity 
(7.4), current MS symptoms (7.3), plaque development (7.3), and safety (6.0). Effect 
on disease progression was 1.8 times more important than influence on lifestyle 
(5.3). Subgroup analysis showed that DMD naïve patients found side effect-related 
attributes far more important than DMD experienced patients. ConClusions: 
Using a thorough method, this study reveals that patients value effectiveness and 
unwanted effects most. Also, heterogeneity was observed in different subgroups. 
Clinicians should be aware of the average preference values and that DMD attributes 
are valued differently by different patients. Person-centred clinical decision-making 
would be needed and requires elicitation of individual preferences.
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exPerimeNt iN muLtiPLe ScLeroSiS
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objeCtives: NICE has suggested that patient preference plays a role in physician 
selection of some Multiple Sclerosis (MS) treatments, but existing patient prefer-
ence surveys are developed using literature rather than patient input. Aims of this 
study were: combine existing literature with patient interviews to develop a dis-
crete choice experiment (DCE) to assess patient preference for MS treatments and 
compare and contrast this information to critically appraise the mixed methods 
approach. Methods: A literature review was conducted to understand patient pref-
erence for attributes of existing MS treatments and inform development of a DCE. 
12 one-to-one telephone interviews were conducted with MS patients. Interviews 
comprised two parts; understanding treatment attributes of importance to patients, 
and detailed cognitive appraisal of the DCE. Team-based framework analysis was 
conducted using interview audio files. Results: Literature and patients interviewed 
generally agreed on key treatment attributes. Although brain lesions were identified 
from literature as a clinical marker, only one patient expressed this as important and 
others either did not understand it or the information was not shared by their clini-
cian. In agreement with literature, patients shared that side effects impacting their 
quality of life were most important, for example fatigue and infection. Feedback on 
the DCE highlighted the importance of consistency between the wording length of 
the attribute level descriptions; patients considered longer descriptions correlated 
with a ‘worse’ level. Interviews also identified questions where language refinement 
was required to improve comprehensiveness. Patients had little knowledge of dis-
ease severity scores contrary to suggestions in the literature, but as disease severity 
was an important concept, this definition was changed. ConClusions: Combining 
patient interviews and existing literature to develop a DCE can have advantages over 
using literature alone: greater confidence that attributes are important to patients, 
early refinement of language and an understanding of patients’ thought processes 
during DCE completion.
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objeCtives: The caregiver-completed Hyperphagia Questionnaire (HQ) is commonly 
used to assess food-seeking behaviours in Prader-Willi syndrome (PWS). A modified 
version, the HQ for Clinical Trials (HQ-CT), was developed and adapted for use in mul-
tinational PWS clinical trials. Methods: The 13-item HQ was reviewed and modified 
based on industry and regulatory standards. The preliminary HQ-CT was included 
in a phase 2 trial; data analysis informed psychometric evaluation and optimal scor-
ing. Further refinements were made following Food and Drug Administration (FDA), 
clinical reviews, and interviews with PWS caregivers in the United States (US). The 
final 9-item HQ-CT was culturally adapted to 10 European languages using industry 
standards for forward-back translation, followed by cognitive debriefing interviews 
(CDIs) with PWS caregivers in target countries to assess content validity. Results: 
Review of the 13-item HQ removed three items to limit content to observable behav-
iours that could change after treatment. Analysis of trial data provided support for 
an HQ-CT composite score (e.g., alpha coefficients ≥ 0.85), as well as the measure’s 
validity and responsiveness. One item was removed based on FDA recommenda-
tion, yielding a 9-item HQ-CT. Interviews with 6 PWS caregivers in the US supported 
content validity. CDIs conducted with 5 PWS caregivers (native-language speakers 
and target-country residents) tested each of the new language translations. Interview 
samples included male and female caregivers, except for the United Kingdom-English 
and the Netherlands-Dutch samples (females only). Respondent ages ranged from 23 
to 64 years across all countries. European caregivers found the HQ-CT content relevant 
and clear. However, there was some difficulty understanding the term ‘hyperphagia’; 
additional text was added to clarify this word. ConClusions: The development of 
the HQ-CT and its adaptation to 10 European languages, with input from 56 caregivers, 
has produced a valuable instrument for assessing food-seeking behaviours in PWS 
clinical trials in the US and Europe.
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a comPariSoN of StateD PrefereNceS for iNjectabLe DiSeaSe-
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objeCtives: Medication compliance with injectable disease-modifying treatments 
(DMTs) for multiple sclerosis (MS) is sub-optimal, with published compliance rates 
ranging from 27% to 83%. This study quantified MS patients’ preferences for features 
of injectable DMTs, and examined whether non-compliant patients have different 
preferences than compliant patients. Methods: Adults with self-reported physi-
cian-diagnoses of MS in Germany (N= 189), the United Kingdom (UK) (N= 100) and 
France (N= 100) completed an online discrete choice experiment survey. Treatment-
experienced respondents reported their level of compliance with their current (or 
most recent) MS medicine and two groups were created: compliant respondents 
(who reported always taking medicine exactly as prescribed) and non-compliant 
respondents (who reported missing less than half, about half, or more than half of 
doses). Respondents were presented with a series of nine treatment-choice ques-
tions wherein hypothetical treatments were described in terms of six attributes. 
Mixed-logit regression parameters were used to calculate preference weights, or 
utilities, of attribute levels and relative importance or, utility differences, of changes 
in attributes for both the compliant and non-compliant respondents. Wald- and 
t-tests of the differences in preferences were conducted. Results: In Germany, the 
UK and France, 81%, 37%, and 73% of the sample reported being compliant, respec-
tively. The relative importance of delaying disability progression for 3 years was 2.7 
times more important among the compliant group than the non-compliant group 
in Germany and the UK (P< 0.05) and 1.1 times more important in France. Among 
compliant respondents, improvements in injection frequency (from 30 to 2 injections 
per month) relative to this improvement in efficacy were 1.5, 6.0, and 2.6 times more 
important to the non-compliant group than the compliant group in Germany, the UK, 
and France. ConClusions: Reductions in injection frequency are relatively more 
important to non-compliant MS patients than to compliant patients, while delay-
ing disability progression was relatively more important to compliant MS patients.
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objeCtives: To estimate patient preferences for relapsing-remitting multiple sclero-
sis (RRMS) treatments Methods: Patients in the United States who reported receiv-
ing a diagnosis of MS from their physician completed a Web-based discrete-choice 
experiment (DCE) survey that included questions on treatment experience and adher-
ence. The survey presented 10 DCE questions in which respondents were asked to 
choose between pairs of hypothetical MS treatment profiles. The profile attributes of 
the treatments were informed by a literature search and clinician input, and tested in 
patient interviews. Attributes included: change in MS progression and years between 
relapses; risk of serious infection; delivery method and frequency of administration; 
and chance of flu-like and gastrointestinal (GI) symptoms. The profiles in the DCE 
questions were based on an experimental design with known statistical properties. 
Random-parameters logit was used to estimate preferences. Results: The sample 
included 301 patients with RRMS: 81% were female; mean age was 54 years; 56% rated 
their disability level as “normal” or “mild”; and 79% reported currently receiving a 
prescription MS treatment. Nineteen percent reported stopping or skipping treatment 
doses due to flu-like symptoms and 9% due to GI symptoms. Respondents placed the 
greatest decision weight on reducing the chance of MS progression and risk of serious 
infection, as well as on the mode and frequency of administration. Followed by daily 
pills, an intravenous (IV) administration every 6 months was preferred over IV every 
month and injections 3 times per week (P < 0.05). Respondents reported being most 
likely to adhere to either daily pills or IV administration every 6 months (39% and 29% 
of patients, respectively). ConClusions: Patients with RRMS reported that treatment 
preferences were influenced by efficacy, reduced side effects, and less burdensome 
modes of administration. Side effects and mode of administration also influenced 
reported likelihood of treatment adherence.
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objeCtives: More than 10 disease modifying drugs (DMDs) are available for relaps-
ing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). Poor 
adherence to DMDs often results in suboptimal (cost-)effectiveness. Understanding 
patients’ preferences for DMD and incorporating them in clinical decision-making 
can contribute to adherence to DMDs. This study aims first to identify the full spec-
trum of DMD attributes and second to quantify their relative importance among 
patients. Methods: First, 3 focus groups with RRMS patients were conducted using 
a nominal group technique to explore attributes for decision-making. Through indi-
vidual generation and discussion of attributes, a full list was created and patients 
selected their 10 most important attributes. Second, a best-worst scaling (BWS) was 
conducted in a larger RRMS/CIS patient group to prioritize attributes. Attributes’ 
mean relative importance scores (RIS) were obtained with Hierarchical Bayes analy-
sis. Results: Nineteen patients participated in the focus groups. A list of 34 attrib-
utes was derived of which 7 were excluded from the BWS because they were never 
